FLINT, Mich. – April 28, 2016 – The nation’s largest independent specialty pharmacy selected to participate in Exelixis, Inc. distribution network for advanced renal cell carcinoma drug CABOMETYX.

Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it has been selected to participate in Exelixis’ limited-distribution panel to distribute CABOMETYX™ (cabozantinib) tablets. CABOMETYX was recently approved by the U.S. Food and Drug Administration to treat patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

To learn more about Diplomat’s oncology program, click here.

RCC is a type of cancer in which malignant cells form in the lining of tubules of the kidney. RCC is the most common form of kidney cancer found in adults, accounting for around 90 percent of all kidney cancers. According to the American Cancer Society, it is estimated that 62,700 people will be diagnosed with kidney cancer in the United States in 2016. The average age at the time of diagnosis is 64. Approximately 17,000 patients in the United States require second-line or later treatment.

“We are pleased to offer patients a therapy that expands their treatment options for advanced kidney cancer,” said Gary Kadlec, Diplomat president. “CABOMETYX tablets offer an important new alternative for patients.”

CABOMETYX is a novel therapy that has demonstrated in a phase 3 trial clinically meaningful improvements for patients with advanced RCC in overall survival, progression-free survival and objective response rate.

CABOMETYX is manufactured by Exelixis, Inc. Please see full prescribing information for CABOMETYX here.

 

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

 

About Diplomat

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.

###

CONTACT:
Kali Lucas, Public Relations Coordinator
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP,
Senior Vice President, Clinical Services,
Education and Human Resources
810.768.9863 | grice@diplomat.is

Twitter